Project Grant R21AI194034
Award Date 8/11/25
Completion Date 7/31/27
Dollars Obligated $453K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Blacksburg, VA, USA
Similar Awards
- This Project Grant award, totaling $155,454, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in Missouri. The award supports research to identify alternative receptors and improve therapeutic decoy molecules for Venezuelan Equine Encephalitis Virus (VEEV), a mosquito-borne virus that causes severe neurological symptoms. The key products and services to be...
- This Project Grant award of $847,000, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on July 15, 2025, will be used to assess the ferret model for evaluating the efficacy of antivirals against Venezuelan Equine Encephalitis Virus (VEEV). The objectives are to evaluate the virology and pathogenesis of the ferret model for the VEEV-INH strain (Aim 1) and to use this model to assess the toxicity, prophylactic, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $414,482 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) on July 24, 2025. The goal of this 2-year project is to enhance the therapeutic efficacy of the Semliki Forest Virus (SFV), a neurotropic oncolytic virus, against glioblastoma, an aggressive form of brain cancer. The project aims to adapt SFV through...
- This $536,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify small molecule inhibitors against critical components of arenaviruses, which cause severe hemorrhagic fevers. The proposed studies aim to use machine learning and molecular screening to identify pan-reactive inhibitors targeting the arenavirus surface glycoprotein and RNA polymerase...
- This Project Grant award of $240,300 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop bispecific antibodies (bAbs) that can efficiently penetrate the blood-brain barrier and deliver neutralizing antibodies against Eastern Equine Encephalitis Virus (EEEV) to the brain. The project will evaluate the therapeutic effectiveness of the bAbs compared to alternative antibody delivery methods...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $808,919 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University. The 5-year grant, which began on September 18, 2025, aims to develop novel aglain derivatives as host-targeted antivirals against dengue virus (DENV) and other mosquito-borne arboviruses. The research program seeks to optimize the aglain chemical series and study their modulation of the host...
- This federal Project Grant award of $3,161,373 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on the transmission dynamics and fitness of the reemerging St. Louis encephalitis virus (SLEV) in mosquito vectors and West Nile virus (WNV) naive and immune avian reservoirs. The research aims to understand the reasons for SLEV's 11-year disappearance from California and its recent...
- This Project Grant award of $128,052.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to study the role of the Rift Valley Fever Virus (RVFV) nonstructural small (NSS) protein in inhibiting the host autophagy pathway. The research will identify the impact of the NSS-LC3 interaction on autophagy, viral replication, and pathogenesis. Key objectives include confirming the NSS-LC3...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $134,577 project grant to the University of California, Los Angeles (UCLA) on January 26, 2025. The grant supports research to elucidate the molecular mechanisms by which encephalitic alphaviruses, such as Sindbis and Chikungunya viruses, can cross the blood-brain barrier and invade the central nervous system. Utilizing a stem...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, has awarded a $720,588 Project Grant to the Regents of the University of Minnesota. The grant supports the "Development of Broadly Protective Vaccines Against New World Arenaviruses" project, which aims to leverage the Pichinde virus vaccine vector to develop safe and effective vaccines against pathogenic New World arenaviruses, such as the...